BIOCRYST PHARMACEUTICALS, INC. (BCRX) Gross margin 2016–2025
BIOCRYST PHARMACEUTICALS, INC. (BCRX) gross margin by fiscal year — reported gross profit divided by reported revenue.
97.8%FY2025 · since FY2016: 91.3% → 97.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 97.8% | +0.5 pp |
| FY2024 | 97.3% | -1.4 pp |
| FY2023 | 98.6% | +1.0 pp |
| FY2022 | 97.6% | +2.2 pp |
| FY2021 | 95.4% | +4.1 pp |
| FY2020 | 91.3% | -1.1 pp |
| FY2019 | 92.4% | — |
| FY2017 | 95.5% | +4.2 pp |
| FY2016 | 91.3% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More BCRX financial trends
BCRX RevenueBCRX Net incomeBCRX Net marginBCRX Gross profitBCRX Operating incomeBCRX Operating marginBCRX Operating cash flowBCRX Free cash flowBCRX Capital expendituresBCRX Return on equityBCRX Stock buybacksBCRX Dividends paidBCRX Total assetsBCRX Total liabilitiesBCRX Shareholders’ equityBCRX overview →